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Abstract
Background The CULPRIT-SHOCK trial compared two treatment strategies for patients with acute myocardial infarction 
and multivessel coronary artery disease complicated by cardiogenic shock: (a) culprit vessel only percutaneous coronary 
intervention (CO-PCI), with additional staged revascularisation if indicated, and (b) immediate multivessel PCI (MV-PCI).
Methods A German societal and national health service perspective was considered for three different analyses. The cost 
utility analysis (CUA) estimated costs and quality adjusted life years (QALYs) based on a pre-trial decision analytic model 
taking a lifelong time horizon. In addition, a within trial CUA estimated QALYs and costs for 1 year. Finally, the cost 
effectiveness analysis (CEA) used the composite primary outcome, mortality and renal failure at 30-day follow-up, and the 
within trial costs. Econometric and survival analysis on the trial data was used for the estimation of the model parameters. 
Subgroup analysis was performed following an economic protocol.
Results The lifelong CUA showed an incremental cost effectiveness ratio (ICER), CO-PCI vs. MV-PCI, of €7010 per QALY 
and a probability of CO-PCI being the most cost-effective strategy > 64% at a €30,000 threshold. The ICER for the within 
trial CUA was €14,600 and the incremental cost per case of death/renal failure avoided at 30-day follow-up was €9010. 
Cost-effectiveness improved with patient age and for those without diabetes.
Conclusions The estimates of cost-effectiveness for CO-PCI vs. MV-PCI have been shown to change depending on the time 
horizon and type of economic evaluation performed. The results favoured a long-term horizon analysis for avoiding under-
estimation of QALY gains from the CO-PCI arm.
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Introduction
Most patients with acute myocardial infarction (MI) com-
plicated by cardiogenic shock have multivessel disease 
with an estimated annual incidence of cardiogenic shock 
of > 45,000 patients in Europe and > 30,000 in the United 
States [1]. Mortality rates for patients with multivessel 
coronary artery disease are higher than for patients with 
single vessel disease ranging between 40 and 70% [2–4]. 
Two alternative strategies for the treatment of multives-
sel disease could be considered. On the one hand, early 
mechanical reperfusion of the culprit lesion by percuta-
neous coronary intervention (PCI) plus staged revascu-
larisation of all other remaining significant lesions could 
be performed. On the other hand, a strategy of immediate 
PCI of all significant stenoses could be followed. Previ-
ous European guidelines for the management of acute 
ST-segment elevation MI recommended immediate mul-
tivessel PCI based mainly on pathophysiological consid-
erations and observational data as there was no data from 
randomised clinical trials [5]. Previous guidelines from the 
United States considered revascularization of both culprit 
and non-culprit arteries during the same procedure to be 
highly appropriate [6].
The multicentre, randomised CULPRIT-SHOCK trial 
investigated whether culprit vessel only PCI (CO-PCI) 
with additional staged revascularisation if indicated was 
more effective than immediate multivessel PCI (MV-
PCI) for patients with cardiogenic shock complicating 
acute myocardial infarction. At 30 days, the composite 
primary endpoint of death and severe renal failure with 
renal replacement therapy was significantly lower in the 
CO-PCI group (45.9%) than in the MV-PCI group (55.4%) 
[Relative risk (RR) of 0.83; 95% confidence interval (CI) 
0.71–0.96] [7]. One year after randomisation the same fig-
ures were 52.0% and 59.5% (RR 0.87; 95% CI 0.76–0.99), 
respectively [8]. These results provoked a reassessment 
of the optimal revascularisation strategy in patients with 
STEMI, multi-vessel disease and cardiogenic shock [9, 
10]. European revascularization guidelines now recom-
mend “culprit lesion-only PCI as the default strategy in 
these patients [11].
This study contributes to the discussion by presenting 
the economic evaluation of the alternative revasculariza-
tion strategies within the CULPRIT-SHOCK trial. A cost 
effectiveness analysis (CEA) and cost utility analysis 
(CUA) is performed to estimate the consequences on med-
ical outcomes, quality adjusted life years (QALYs) and 
costs during the trial period. A pre-trial decision analytic 
model was used to analyse long term cost-effectiveness 
of CO-PCI vs. immediate MV-PCI [12]. The need for an 
economic analysis is justified given different consequences 
for healthcare costs. For example, there was more repeat 
revascularisation of non-culprit lesions and rehospitali-
sation for heart failure in the CO-PCI arm than in the 
MV-PCI group but more patients died or required renal 
replacement therapy in the MV-PCI group [8].
Methods
Population, setting and location, and comparators.
The CULPRIT-SHOCK trial population are patients with 
acute MI, cardiogenic shock, and multivessel coronary 
artery disease from 83 European centres. Seven hundred 
and six patients were randomised to the two different 
revascularization strategies: CO-PCI or immediate MV-
PCI. Full informed consent was obtained for 686 patients. 
The details of the methods and design of the trial have 
been published previously as well as the clinical outcome 
for the 30-day primary endpoint and the 1-year follow-up 
[7, 8, 13].
Economic evaluation and time horizon
The cost utility analysis (CUA) estimated all costs and 
quality adjusted life years (QALYs) based on a pre-trial 
decision analytic model taking a lifelong time horizon. In 
addition, a within trial period CUA estimated QALYs and 
cost by running the model for up to 1 year after randomi-
sation. The cost effectiveness analysis (CEA) used the 
composite primary outcome, mortality and renal failure 
at 30-day follow-up, and the within trial costs.
Perspective, guidelines and discounting
Given that a majority of patients were from Germany, the 
economic evaluation took a German societal and National 
Health Service perspective, considering productivity costs 
in addition to health care costs. The economic analysis fol-
lowed guidelines of the Institute for Quality and Efficiency 
in Health Care, good practice in health technology assess-
ment and the CULPRIT-SHOCK economic protocol [12, 
14, 15]. The analysis was based on an intention-to-treat 
principle. A 3% discount rate was applied to future costs 
and QALYs.
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Measurement and valuation of costs and health 
outcomes
Resource use was collected at baseline, 30-day, 6-month 
and 12-month follow-up. The resources used were val-
ued at unit costs provided by the Institute for the Hospital 
Remuneration System (InEK) using diagnosis related 
groups (DRGs). Medication prices were obtained from the 
German Institute of Medical Documentation and Infor-
mation (DIMDI).1 Unit costs from the literature were 
used where required [16–22] (details in supplementary 
material).
Survival data from the trial was used to estimate the prob-
ability of different health conditions. Time spent in each 
health condition was weighted by quality of life using the 
EuroQol five-dimension three-level (EQ5D) instrument, 
Fig. 1  Decision tree. Previously 





























Fig. 2  Markov model. Previ-










1 The British National Formulary (BNF) was used where medication 
prices were not available at the DIMDI.
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reported by patients at 30-day, 6-month and 12-month fol-
low-up [23]. The EQ5D was valued by the German value 
set [24].
The model
A published pre-trial cohort model allowed us to estimate 
costs and effects for the economic evaluation [12].
Structure: decision tree and Markov model
The model is shown in Fig. 1, for the 1-year decision tree, 
and Fig. 2, for long-term Markov model. For each revas-
cularization strategy, the first node in Fig. 1 represents the 
uncertainty for a patient to die or survive 30 days after the 
medical intervention. All those who survive the first month 
go through a second node that gives place to different end-
points: death, renal failure, heart failure, major adverse car-
diac event (MACE) and alive and stable (A&S). The health 
states are assumed mutually exclusive, i.e., a patient could 
only experience one health outcome. Given that a patient 
could experience more than one health state in practice, we 
applied the next definitions. A patient was in Death state if 
they died from any cause. Renal failure was the state for a 
patient receiving renal replacement therapy and surviving 
1 year after randomisation. A patient was in the heart failure 
state if re-hospitalised for that reason and was not dead or 
in renal failure. MACE included all those patients who suf-
fered a major adverse cardiovascular event (i.e., MI, stroke 
or revascularisation) during the first year after the treatment 
but did not suffer heart failure, renal failure or death. Finally, 
A&S was the residual health condition for all patients that 
are not included in any of the remaining states.
Patients who survive 1 year after randomisation move to 
the Markov model stage shown in Fig. 2. A monthly-cycle 
model allows patients to move to different health states in 
the long-term. Patients can die or remain in their chronic 
condition: renal failure, heart failure and A&S. Patients with 
MACE at the end of the decision tree period are assumed to 
move back to health state A&S if MACE does not recur and 
they do not die. All patients in chronic states can suffer from 
MACE and change condition in the next cycle. Only patients 
who remain A&S can transit to renal or heart failure, but the 
opposite pathway is not possible. Finally, patients can switch 
to a death state from any health state. All the transitions are 
assumed to happen at the beginning of each period.
Parameters




Transition probabilities Transition probabilities for the 
decision tree were estimated from raw frequencies of each 
health state at 30-day and 12-month follow-up. The transi-
tion probabilities for CO-PCI were computed by applying 
relative risks of death, renal failure, heart failure, and MACE 
to transition probabilities for MV-PCI. These relative risks 
were estimated for each event separately using trial data.
Transition probabilities in the long term are probability of 
death from any health state; renal failure; MACE, and rehos-
pitalisation for heart failure. Survival analysis was applied to 
the within trial data to estimate long-term probabilities for 
the Markov model. Parametric models were used to fit the 
within trial data following methodological guidelines in the 
literature [25]. Transition probabilities are estimated con-
ditional on patient characteristics (age, gender and whether 
the patient is diabetic) and trial arm. Mortality estimated 
for the Markov model is also conditional on health states. 
To avoid unrealistic predictions of death probabilities in the 
long term, survival analysis was used to predict mortality for 
the first cycle of the Markov model, thereafter, probability 
of death was assumed to change proportionally to mortality 
rates given by life tables [26].
Utilities The model incorporated quality of life by weight-
ing time on each health state by a health utility score esti-
mated from trial data. The EQ5D health utilities for each 
patient were used to estimate a random effect econometric 
model including the health state as explanatory variable; the 
individual patient was included as the panel variable. This 
model controlled for other variables such as: age, gender, 
diabetes disease, body mass index (BMI), history of cardio-
vascular disease and risk factors. Utilities could vary among 
health states but not between trial arms. Differences in qual-
ity of life between arms came from differences in frequency 
of health states. Finally, a zero utility was assigned to the 
death-state.
The health utility attached to MACE in the long term was 
changed with respect to the utility of MACE in the decision 
tree. A substantial proportion of MACE in the first year were 
patients having staged revascularization due to a medical 
decision, taken within the scope of the revascularization 
strategy. It was considered that the health utilities derived 
for those patients would not be an accurate prediction for 
patients suffering a cardiac event in the future. For the long 
term, the same utility model explained above was estimated, 
where only patients with urgent revascularization, MI or 
stroke were included in the MACE state.
Costs The estimation of costs included in the model var-
ied for the first-year decision tree and the long-term Markov 
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model. For the first year, a within trial cost was estimated for 
each arm, where all the resources used were valued by the 
unit costs. The list of costs collected included: repeat revas-
cularization/PCI; hospitalization after PCI, differentiating 
between intensive care unit (ICU) or normal ward; inpa-
tient hospitalization and emergency room visits at follow-
up; medications; stents; angiography; internal cardioverter 
defibrillators (ICD); extracorporeal membrane oxygenation 
(ECMO) procedures; intra-aortic balloon pump (IABP) pro-
cedures; left ventricular assist devices (LVAD); heart trans-
plants; investigations; renal replacement therapy, and; pro-
ductivity losses. All the cost information was reported in the 
electronic case report form (eCRF) completed by the treat-
ing clinicians; except for inpatient hospitalization, visits to 
emergency room and productivity losses that were reported 
by patients and confirmed by hospital and/or general prac-
titioners reports.
The estimation of some costs is explained in more detail 
below:
– Hospitalization costs Hospitalization after index PCI, 
ICU and normal ward, was collected using eCRF. In 
addition, patients reported inpatient hospitalization at 
30-day follow-up. To avoid double counting in hospi-
talization costs, we did not include self-reported inpatient 
hospitalization at 30-day follow-up for the computation 
of the cost of each treatment alternatives.
– Renal replacement therapy All the patients that received 
renal replacement therapy were attached a one-time cost 
for therapy costs. If the patient survived 1 year after ran-
domisation, an additional cost of dialysis was included 
to account for cost of dialysis for that period.
– Angiography A cost for diagnosis related group (DRG) 
was considered for each patient undertaking angiography. 
To account for the number of angiographies and time 
spent, we assigned the DRG cost in proportion to the 
total time the patient spent in a fluoroscopy.
– Productivity costs Patients reported the number of days 
of work lost. A friction period of 60 working days (8 h) 
was assumed for patients who left work for more than 
60 days or dies before age 65. For patients that left paid 
work but returned to unpaid work after revascularization, 
a cost of 30 working days was imputed. If the patient 
reduced working hours at work, a cost of 10 working 
days was assumed. Patients that did not work before ran-
domization had zero cost.
– Medications We had information about whether a patient 
was prescribed or administered a specific medication dur-
ing hospitalization at ICU or normal ward after PCI. We 
assumed that the medication was administered for the 
time spent at the hospital. A standard dose per day was 
assumed following opinion from experts involved in the 
trial and the British National Formulary (BNF).
In the long-term model, a cost was attached to each cycle 
conditional on health state based on a random effect econo-
metric model that estimated hospitalization and emergency 
room costs using information for 6- and 12-month follow-up, 
where the patient was the panel variable. Explanatory vari-
ables and specification of this model are the same as for the 
utility model explained above.
The unit costs considered in the analysis are shown in the 
Online Appendix.
Missing values and outliers
Missing values for hospitalization and emergency room 
visits were imputed algorithmically. Missing values were 
converted to zero for all those patients that died before they 
could have any hospitalization at each follow-up period. In 
other cases, missing values were replaced by the average 
value conditional to survival/death at each specific follow-
up. The complete case analysis was performed for all other 
variables used in the study.
Outliers were identified and eliminated when statistically/
unrealistically diverged from the sample distribution.2
Cost effectiveness outcome
The economic evaluation was intended at estimating the 
incremental cost effectiveness ratio (ICER), where the effec-
tiveness measure is either QALY or percentage of death/
renal failure for the CUA or CEA, respectively. In addition, 
the net monetary benefit was estimated for a range of policy 
relevant monetary values of a QALY to build the cost effec-
tiveness acceptability curves (CEACs).
Probabilistic sensitivity analysis
Monte Carlo simulation was used to perform the probabilis-
tic sensitivity analysis. The model parameters were assumed 
to vary according to specific distributions with parameters 
estimated from trial data. Lognormal distributions were 
assumed for the relative risks and beta distributions for 
absolute risk. For costs, Gamma distributions were used. 
Finally, Beta distributions were considered for utilities and 
incremental utilities.
Subgroup analysis
Per protocol predefined subgroup analysis was performed 
to study the heterogeneity of the results for: age groups 
2 Patients with more than 365  days of hospitalisation or more than 
7 h of fluoroscopy were considered outliers. Less than 1% of patients 
met one of these two criteria.
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(< 50 years, 50–75 years, > 75 years); sex, and patients 
with/without diabetes. The parameters of the model were 
adapted to each subgroup. The treatment effect on decision 
tree probabilities estimated for the total sample was applied 
to baseline probabilities for each trial subgroup. Markov 
model transition probabilities were also specific for each 
subgroup according to the survival analysis estimations. 
Health utilities were adjusted to the average of each sub-
group for patients in the state A&S. The absolute differential 
effect of each health state was assumed the same for all sub-
groups. Costs were estimated/computed for each subgroup 
separately considering the resource use within 1 year after 
randomisation and the frequency of each health state in long 
term costs.
Software
The model results were obtained using the package ‘heemod’ 
for the statistical software R [27, 28]. All statistical and 
econometric analyses were performed using STATA 14.0 




The estimated frequencies for each health state of the deci-
sion tree are shown in Table 1. At 30-day follow-up, the 
death rate was lower in the CO-PCI arm than in the MV-PCI 
group (43.3% v. 51.5%) with a statistically significant rela-
tive risk (0.84, p value = 0.033). Conditional to surviving 
the first 30 days after randomisation, death rate was simi-
lar in both groups between 30 days and 12-month follow-
up (11.8% and 10.8%, respectively; relative risk of 1.09, 
p value = 0.777). The conditional probability of being in 
MACE is significantly higher for the culprit-only revascu-
larization strategy than for the multivessel PCI group (44.6% 
vs. 19.9%). A closer inspection reveals that these differences 
are driven by a higher rate of repeat revascularization per-
formed in the CO-PCI arm; the rate of stroke or MI was 
not significantly different between groups as reported in the 
main efficacy analysis [8]. Finally, the CO-PCI strategy had 
a higher probability of heart failure (relative risk of 2.55, p 
value = 0.099) and a lower frequency of renal failure (rela-
tive risk of 0.66, p value = 0.403), conditional to being alive 
30 days after randomisation. Therefore, the number of peo-
ple being in A&S, conditional to surviving the first 30 days 
after revascularization, is statistical significantly higher for 
the MV-PCI arm.
Details of survival analysis for the estimation of transition 
probabilities in the long term are described in the Online 
Appendix. Different parametric survival models were con-
sidered: exponential, Gompertz, Weibull, loglogistic and 
lognormal. Given the patterns shown for mortality rates, 
with deaths concentrated in the first 30 days after randomisa-
tion, death transition probabilities were estimated by fitting 
data for the period 30 days to 1 year after randomisation. 
The Weibull model was the best fit according to the Akaike’s 
information criterion (AIC) and Bayesian information crite-
rion (BIC). No statistically significant differences between 
trial arms were estimated (p value = 0.953). Only a statisti-
cally significant higher mortality hazard was estimated for 
patients with diabetes with respect to the non-diabetes sub-
group (p value = 0.01). Hazard rate also increased (no sta-
tistical significance, p value > 0.05) for patients with health 
conditions (renal failure, heart failure and MACE), older age 
and male gender. The exponential model was the best fit for 
the estimation of heart failure hazard. Only a significantly 
higher hazard was estimated for the CO-PCI arm vs. the 
MV-PCI group (p value = 0.01). In the case of MACE, the 
best-fit model was lognormal and a higher hazard for the 
CO-PCI strategy was estimated (p value = 0.048). Finally, 
no new patients required renal replacement therapy after the 
first 19 days from randomisation, so the risk of renal failure 
was assumed zero in the long term.
Health utilities Table  2 shows the EQ5D health utilities 
by arm and follow-up. There were no statistically signifi-
cant differences between arms at any follow-up. Nonethe-
less, quality of life for both trial arms improve over time as 
health utilities at 12-month follow-up tend to be higher than 
at 6-month and at 30-day follow-up. Finally, Table 3 reports 
the results for the utility model estimating differences 
between health states. Our estimates suggest that there was 
Table 1  Probability of endpoints of decision tree
Probabilities for the period 30 days to 1 year after randomization are 
conditional to survival 30  days after randomization, i.e., number of 
patients in each health state divided by the number of patients alive at 
30-day follow-up




 Death 43.3 51.5 0.84 0.033
30 days to 1 year
 Death 11.8 10.8 1.09 0.777
 Renal failure 3.6 5.4 0.66 0.403
 Heart failure 6.2 2.4 2.55 0.099
 MACE 44.6 19.9 2.24 < 0.001
 A&S 33.8 61.4 0.55 < 0.001
N 344 342
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not any statistically significant effect of any health condition 
(heart failure, renal failure, MACE) with respect to A&S. 
Nonetheless, health utilities estimates were higher, for 
MACE, and lower, for renal failure and heart failure, with 
respect to A&S. The effect of suffering MACE on health 
utilities was not statistically significant when only patients 
with urgent revascularization, MI or stroke were included 
(p value = 0.707). For the subgroup variables, we estimated 
a lower health utility for older patients, females and diabe-
tes condition (no statistically significant at 10%). The only 
statistically significant control variable was history of CVD 
with a negative impact on utility (p value = 0.052).
Costs Resource use and monetary costs for the first year 
after randomisation are shown in Table 4. The cost was not 
statistically significantly different between arms for most 
categories. Nonetheless, some patterns were consistent 
with the clinical results and with the characteristics of each 
revascularization strategy. CO-PCI patients incurred more 
in repeat revascularization and ICU costs, while patients in 
MV-PCI had more costs related to renal replacement therapy 
(continuous dialysis), number of stents and angiography. 
Total cost did not significantly differ between revasculariza-
tion strategies (p value = 0.679), although it was higher for 
the CO-PCI arm on average by €841 per patient.
The cost model is shown in Table 5, where hospitali-
zation and emergency room costs reported at 6-month and 
12-month follow-up were regressed against health states and 
control variables. A higher cost is estimated for all the health 
conditions compared to A&S, but only estimates for heart 
failure are statistically significant at 10%. In the long-term 
Markov model, a monthly cost was attached to each cycle, 
conditional on health state, based on the estimates.
Cost‑effectiveness results
The results for the base-case analysis are shown in Table 6 
rounded to 3 significant figures. The percentage of death/
renal failure was significantly higher in the MV-PCI arm 
(0.0933; 95% CI 0.0225, 0.159). As a result, the average 
ICER for the CEA was €9010 per case of death/renal failure 
avoided. With respect to the CUAs, the results are based 
on the parameters estimated and summarised for the deci-
sion tree and Markov model in the Online Appendix. If we 
restrict the analysis to the within trial period, the CO-PCI 
strategy entails an increase of 0.0577 QALYs per patient 
(95% CI − 0.00275, 0.114) with an average ICER about 
14,600 €/QALY. However, a huge uncertainty remains as 
shown in the confidence interval.
The lifelong analysis shows non-significant differences 
in costs and QALYs. The average cost for CO-PCI arm 
are about €2060 (95% CI − 2370, 10,500) higher than for 
the MV-PCI arm, which is more than double the differ-
ence estimated for the within trial period. Nonetheless, 
the lifelong QALY increment for the CO-PCI strategy is 
0.293 (95% CI − 0.69, 1.51) per patient, which is about 
five times higher than the figure estimated for the first 
year after randomisation. The consequence of considering 
a long-term perspective is an average ICER approximately 
Table 2  EQ5D health utilities
The number of observations for each group are those patients who survive to each follow-up period with no 
missing information
Follow-up CO-PCI MV-PCI Incremental
Mean N Mean N Mean p value
30 days 0.756 171 0.728 143 0.028 0.430
6 months 0.833 161 0.815 138 0.018 0.533
12 months 0.842 155 0.845 132 − 0.004 0.891
Table 3  Health utility model
The constant of the model represents a female patient, in the A&S 
state, younger than 50, with no diabetes, normal or underweight, no 
CVD history and no risk factors. The coefficient of MACE changed 
to 0.0104 (p value = 0.707) if only patients with urgent revasculariza-
tion, MI or stroke were included
Coef p value
Health state (ref. A&S):
 HF − 0.051 0.294
 MACE 0.036 0.130
 RF − 0.085 0.161
Control variables
Age (ref. < 50)
 50–75 − 0.0003 0.996
 > 75 − 0.079 0.208
Male 0.041 0.242
Diabetes − 0.036 0.264
BMI (ref. normal or underweight)
 Overweight − 0.013 0.663
 Obese − 0.0004 0.991
CVD history − 0.057 0.052
Risk factor 0.041 0.308
Cons 0.773 0.000
N—number of patients 322
N—number of patient-follow-ups 875
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Table 4  Average resource use and costs during 1 year after randomization
Medication are expressed in days receiving the standard dose, except for the case of GP IIb/IIIa-inhibitors, UF heparin, bivalirudin and catecho-
lamine therapy, where proportion of patient receiving medication is shown
Resource use (units/patient) Cost (€/patient)
CO-PCI MV-PCI Incremental CO-PCI MV-PCI Incremental p value
Number of urgent/staged PCIs 0.324 0.093 0.231 1052 302 751 < 0.001
Hospitalizations
ICU nights 7.832 7.526 0.305 7522 7229 293 0.679
Normal ward nights 5.246 5.820 − 0.574 1500 1664 − 164 0.432
Impatient days 2.138 3.758 − 1.620 611 1074 − 463 0.243
Emergency room visits 0.381 0.259 0.122 149 101 48 0.486
Number of renal rep. therapy
Continuous dialysis 0.044 0.093 − 0.049 35 75 − 40 0.013
Hemodiafiltration 0.031 0.028 0.003 29 26 3 0.806
Hemofiltration 0.025 0.034 − 0.009 24 33 − 9 0.494
Intermittent dialysis 0.016 0.012 0.003 4 3 1 0.731
Number renal failure long term 0.019 0.028 − 0.009 1211 1806 − 594 0.441
Stents 2.688 3.582 − 0.894 185 246 − 61 < 0.001
Angiography (minutes in fluoroscopy) 18.353 22.540 − 4.187 426 523 − 97 < 0.001
Number of ICDs 0.040 0.043 − 0.003 113 121 − 8 0.857
Number of ECMOs 0.062 0.102 − 0.040 600 984 − 384 0.066
Number of IABPs 0.090 0.080 0.010 115 102 12 0.655
Number of LVADs 0.140 0.118 0.023 6046 5074 972 0.407
Number of heart transplants 0.003 0.000 0.003 62 0 62 0.316
Number of investigations procedures
Scintigraphy 0.003 0.000 0.003 0 0 0 0.316
Stress-echocardiogram 0.000 0.015 − 0.015 0 0 0 0.025
MRI 0.006 0.000 0.006 2 0 2 0.156
Days of medications
Aspirin 12.545 13.250 − 0.706 0 0 − 0 0.570
Clopidogrel 6.274 6.666 − 0.392 70 74 − 4 0.720
Prasugrel 3.625 4.114 − 0.490 5 6 − 1 0.531
Ticagrelor 4.777 4.455 0.322 7 6 0 0.692
Vitamin-K-antagonists 1.628 1.407 0.221 3 3 0 0.687
GP IIb/IIIa-inhibitors 0.224 0.220 0.004 42 41 1 0.891
UF heparin 10.439 10.524 − 0.085 0 0 − 0 0.942
LMW heparin 1.620 2.584 − 0.964 25 39 − 15 0.118
Bivalirudin 0.050 0.068 − 0.018 25 34 − 9 0.326
Fondaparinux 0.380 0.573 − 0.193 0 1 − 0 0.566
Beta-blocker 10.465 10.035 0.430 94 90 4 0.713
ACE-inhibitor/AT-II-antagonist 9.503 8.743 0.760 14 13 1 0.499
Statins 11.095 11.043 0.052 43 43 0 0.965
Calcium-antagonist 1.734 1.308 0.426 0 0 0 0.416
Aldosterone-antagonist 3.690 4.082 − 0.392 4 5 − 0 0.664
Diuretics 9.042 8.048 0.994 0 0 0 0.376
Edoxaban 0.022 0.000 0.022 0 0 0 0.316
Apixaban 0.257 0.310 − 0.053 1 1 − 0 0.811
Rivaroxaban 0.595 0.121 0.474 1 0 1 0.035
Dabigatran 0.204 0.337 − 0.133 0 0 − 0 0.596
Catecholamine therapy 6.406 6.657 − 0.251 6 7 − 0 0.133
Work hours lost 154.642 139.022 15.620 5343 4803 540 0.365
Total 25,371 24,531 841 0.679
N 321 323 321 323
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7010 €/QALY, less than half the estimate from the within 
trial CUA. The uncertainty around the estimates is rep-
resented in the cost effectiveness plane (CEP) and cost 
acceptability curves (CEAC) shown in Figs.  3 and 4, 
respectively. The simulation points are spread over the four 
quadrants of the CEP. However, most of the simulation 
points (about 58%) are in the upper-right quadrant of the 
CEP implying that CO-PCI tended to be both more costly 
and effective. Finally, the CEAC shows that the CO-PCI is 
the most (less) likely cost-effective strategy for any mon-
etary value of a QALY higher (lower) than €9000. Indeed, 
the probability of CO-PCI being cost-effective is higher 
than 64% for any threshold above 30,000 €/QALY.
Subgroup analysis
The subgroup analyses for age, gender and diabetes can 
be compared in Table 7. The results for the total sample 
are mainly replicated for all the subgroups, i.e., the CO-
PCI strategy is the costliest and most effective. However, 
some differences between subgroups appear with respect 
to the cost-effectiveness of the strategies being evaluated. 
For example, the cost effectiveness of CO-PCI improves 
for older subgroups. For patients aged > 75 this treatment 
alternative is dominant, meaning that on average is both 
more effective and less costly. On the contrary, for the 
youngest subgroup, age < 50, the average ICER was about 
117,000 €/QALY and the probability of CO-PCI being the 
most cost-effective alternative is lower than 43% for any 
monetary value of a QALY below €50,000 (see Online 
Appendix for CEPs and CEACs for subgroups). The cost 
effectiveness of the CO-PCI decreases for patients with 
diabetes with an ICER of 14,700 €/QALY compared to 
patients without this condition with an ICER of 5680 €/
Table 5  Cost model
The constant of the model represents a female patient, in the A&S 
state, younger than 50, with no diabetes, normal or underweight, 
no CVD history and no risk factors. MACE included patients with 
urgent revascularization, MI or stroke
Coef p value





Age (ref. < 50)
 50–75 254.8 0.800
 > 75 224.4 0.843
Male 509.0 0.425
Diabetes 6.2 0.992
BMI (ref. normal or underweight)
 Overweight 27.0 0.962
 Obese − 447.3 0.531
CVD history 425.9 0.430
Risk factor 260.6 0.718
Cons − 19.1 0.988
N—number of patients 322
N—number of patient-follow-ups 634
Table 6  Economic evaluation results: costs, effects and ICERs
Effectiveness measure for CEA is % reduction of composite outcome death or renal-replacement therapy at 30-day follow-up. Figures are 
rounded to 3 significant figures
CO-PCI culprit only percutaneous coronary intervention, MV-PCI multivessel percutaneous coronary intervention.
Intervention strategies Costs (€/patient) Effect (per patient) ICER
Mean [95% CI] Mean [95% CI] Mean [95% CI]
CEA % death/renal problem (30-day FU) €/case
 CO-PCI 25,400 [22,600, 28,200] 0.541 [0.457, 0.615]
 MV-PCI 24,500 [21,800, 27,500] 0.447 [0.393, 0.5]
 CO-PCI vs. MV-PCI 841 [− 3360, 4780] 0.0933 [0.0225, 0.159] 9010 [− 45,400, 83,200]
CUA (1-year FU) QALYs €/QALY
 CO-PCI 25,400 [22,600, 28,200] 0.398 [0.319, 0.478]
 MV-PCI 24,500 [21,800, 27,500] 0.34 [0.285, 0.394]
 CO-PCI vs. MV-PCI 841 [− 3360, 4780] 0.0577 [− 0.00275, 0.114] 14,600 [− 111,000, 178,000]
CUA (lifelong) QALYs €/QALY
 CO-PCI 27,200 [23,500, 37,700] 2.94 [1.09, 5.49]
 MV-PCI 25,100 [22,400, 29,,400] 2.64 [0.951, 4.83]
 CO-PCI vs. MV-PCI 2060 [− 2370, 10,500] 0.293 [− 0.69, 1.51] 7010 [− 92,200, 107,000]
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QALY. No substantial differences in cost effectiveness 
have been found between gender groups.
Discussion
The within trial data provided evidence for costs, health 
states distribution and health utilities of CULPRIT-
SHOCK patients up to 1  year from randomisation. In 
addition, econometric and survival analysis estimated 
parameters for the pre-trial model making the projection 
of cost effectiveness of CO-PCI vs. MV-PCI in the long 
term possible. The results showed that it is important to 
undertake a long-term approach as it derives from the dif-
ferences between the within trial and lifelong analysis. 
Only considering within trial analysis, CO-PCI would be 
cost effective for a monetary value of at least €14,600 per 
QALY. The long-term analysis reduced the ICER to about 
€7000 per QALY, indicating an underestimation of QALY 
gains when a short-term horizon was considered. Given 
the survival gains estimated in the short term (at 30-day 
follow-up), cost-effectiveness improves as time horizon 
increases. Even in the case that mortality rates did not 
differ between arms in the long term (i.e., after the 1-year 
trial period), as it seems to be the case here, QALYs would 
accumulate over time due to short term reduced mortal-
ity. This pattern can be found in previous studies [23–32]. 
Nonetheless, higher incremental costs were estimated for 
the CO-PCI arm when a lifelong CUA was compared to 
a within trial analysis; consistently with a higher risk of 
heart failure and MACE. Finally, subgroup analysis seems 
to reveal some patterns that are worthwhile to have into 
account. The cost-effectiveness of CO-PCI vs. MV-PCI 
increases with age and for the non-diabetes patients. 
Although results are similar between patients classified 
by gender.
This study presents the first economic evaluation based 
on randomised data comparing MV-PCI vs. CO-PCI for 
patients with acute MI and cardiogenic shock. Cohort or 
registry studies have limitations for interpreting differences 
between arms as causal effects. In the context of MI com-
plicated by cardiogenic shock, physician discretion to deter-
mine treatment strategy (complete vs. culprit only PCI) has 
been acknowledged to incorporate a selection bias in the 
estimations of outcomes [33]. A strength of this analysis is 
the use of data from the Culprit-Shock trial, avoiding selec-
tion bias by randomly allocating patients to treatment groups 
[9].
The analysis followed a health economic analysis plan 
(HEAP) that established different details of the economic 
evaluation like time horizon, outcomes and variables, sta-
tistical methods, sources of information and a decision ana-
lytic model [12]. The advantages of using HEAPs to guide 
economic evaluations have been acknowledged in the health 
economics literature, particularly regarding transparency and 
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Fig. 4  CEAC. Lifelong CUA base case analysis
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protocols has been increasing in the last few years [36–39]. 
However, the use of a published pre-trial model introduces 
an innovative aspect, since few HEAPs contain a detailed 
decision analytic model for a long-term analysis [40].
The long-term results must be interpreted in line with 
the strategy used for the estimation of model parameters. 
For example, statistical measures and visual inspection have 
been applied to choose parametric survival models that best 
fitted within trial data. Nonetheless, this extrapolation strat-
egy may have problems if hazard rates change substantially 
in the long term. In the CULPRIT-SHOCK trial, mortality 
risk is higher in the MV-PCI arm. However, after 30-day 
follow-up, the pattern seems to change with non-statistically 
significant differences in mortality between arms favouring 
the MV-PCI. A change in mortality rates comparing short 
to long term has also been found in non-randomised studies 
[41, 42]. Based on this evidence, and following guidelines, 
two main modelling decisions were taken to improve clinical 
and external validity of extrapolation of mortality risk [25]. 
First, only the period after 30-day follow-up have been con-
sidered for the estimation of death risk. And second, mortal-
ity was assumed to change proportionally to life tables rates 
to avoid unsustainable survival rates in the long-term.
Another feature of the results is the uncertainty about cost 
effectiveness. A substantial probability for MV-PCI being 
more cost-effective remains, ranging 35–33% for thresh-
olds 30,000–50,000 €/QALY (lifelong model). Uncertainty 
comes from the estimated parameters; especially long-term 
probability of death, heart failure and MACE. For example, 
long-term mortality rate, extrapolated from 30-day to 1-year 
follow-up data, was not statistically significantly different in 
CO-PCI compared to MV-PCI. However, the inclusion of 
Table 7  CUA (lifelong). Subgroups
Figures are rounded to 3 significant figures. N represents the distribution of participating patients according to subgroup characteristics
CO-PCI culprit only percutaneous revascularisation, MV-PCI multivessel percutaneous revascularisation.
Intervention strategies N Costs (€/patient) Effect (per patient) ICER
Mean [95% CI] Mean [95% CI] Mean [95% CI]
Age < 50 QALYs €/QALY
 CO-PCI 17 51,900 [38,600, 74,700] 7.88 [2.18, 13.5]
 MV-PCI 16 42,800 [31,100, 55,500] 7.8 [2.23, 13.5]
 CO-PCI vs. MV-PCI 33 9090 [− 8240, 30,400] 0.0774 [− 2.16, 1.97] 117,000 [− 286,000, 153,000]
Age 50–75 QALYs €/QALY
 CO-PCI 212 38,600 [33,400, 52,600] 3.91 [1.45, 7.03]
 MV-PCI 227 36,100 [32,500, 42,300] 3.62 [1.32, 6.21]
 CO-PCI vs. MV-PCI 439 2500 [− 3610, 12,800] 0.295 [− 0.953, 1.73] 8500 [− 84,000, 108,000]
Age > 75 QALYs €/QALY
 CO-PCI 115 17,500 [13,600, 23,700] 0.947 [0.258, 2.65]
 MV-PCI 99 17,800 [13,500, 23,200] 0.744 [0.275, 1.98]
 CO-PCI vs. MV-PCI 214 − 226 [− 6970, 7010] 0.203 [− 0.335, 1.05] CO-PCI dominates
Female QALYs €/QALY
 CO-PCI 86 21,800 [15,500, 35,100] 3.21 [1.21, 5.88]
 MV-PCI 75 19,000 [14,700, 25,900] 2.86 [1.04, 5.06]
 CO-PCI vs. MV-PCI 161 2810 [− 4610, 14,200] 0.347 [− 0.734, 1.6] 8080 [− 95,300, 105,000]
Male QALYs €/QALY
 CO-PCI 257 29,100 [25,000, 39,500] 2.86 [1.05, 5.65]
 MV-PCI 267 26,900 [23,700, 31,900] 2.58 [0.928, 4.89]
 CO-PCI vs. MV-PCI 524 2160 [− 2880, 10,100] 0.28 [− 0.721, 1.56] 7740 [− 130,000, 94,000]
No diabetes QALYs €/QALY
 CO-PCI 241 27,300 [22,700, 39,800] 3.58 [1.39, 6.52]
 MV-PCI 226 25,300 [22,000, 30,700] 3.24 [1.19, 5.72]
 CO-PCI vs. MV-PCI 467 1970 [− 3380, 11,400] 0.346 [− 0.805, 1.69] 5680 [− 82,500, 66,900]
Diabetes QALYs €/QALY
 CO-PCI 102 27,200 [21,900, 36,500] 1.88 [0.642, 4.12]
 MV-PCI 116 24,700 [20,300, 30,500] 1.71 [0.615, 3.59]
 CO-PCI vs. MV-PCI 218 2520 [− 5000, 11,400] 0.172 [− 0.605, 1.18] 14,700 [− 169,000, 196,000]
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this estimate adds uncertainty to the results. Even more, the 
long-term analysis comes at a higher uncertainty because of 
the extrapolation exercise. Two scenarios were considered to 
illustrate the statistical uncertainty under different extrapo-
lation hypothesis (see Online Appendix). In scenario 1, we 
assumed no differences between arms in risk of death in the 
long term. The consequence was a > 75% of CO-PCI being 
cost-effective for a threshold of 30,000€/QALY. In scenario 
2, we assumed no differences between arms in risk of death, 
heart failure and MACE in the long term. The same prob-
ability of CO-PCI being cost-effective increased to > 90%.
The cost-effectiveness impact of the two revasculariza-
tion approaches in multivessel disease complicated by car-
diogenic shock is based on an intention to treat principle 
according to good research practice [43]. In this sense, cross-
overs were possible due to medical decisions or technical 
reasons. For example, 43 (12.5%) patients in the CO-PCI 
arm undertook immediate multivessel PCI. On the other 
hand, 32 (9.4%) patients allocated to the MV-PCI were not 
treated with immediate PCI of non-culprit lesions. In addi-
tion, the generalisability of the results relies on whether 
revascularisation procedures are followed in line with the 
CULPRIT-SHOCK definitions. For example, some studies 
may consider different definitions of complete multivessel 
revascularization [44].
Conclusion
On average, results favour the CO-PCI strategy as the most-
cost effective strategy if the monetary value of a QALY is 
higher than €7010. However, substantial uncertainty remains 
even at a threshold of €30,000 per QALY, mainly due to 
extrapolation of long-term parameters from the trial data. 
This uncertainty would be widely reduced if we were cer-
tain that there was no direct treatment effect after the trial 
period in key parameters like long term mortality, heart fail-
ure or MACE. Finally, results show that cost-effectiveness 
improves with age of the patient and for the non-diabetes 
groups.
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